Login to Your Account



Scancell to Bolster Cash by $10M, Advance Moditope Work

By Nuala Moran
Staff Writer

Wednesday, July 10, 2013
LONDON – Cancer immunotherapy specialist Scancell Holdings plc is looking to raise £6.5 million (US$9.7 million) in a placing and open offer, allowing it to expand an ongoing Phase I/II trial of its lead Immunobody product, SCIB1 , and to commence preclinical development of a second cancer vaccine platform, Moditope.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription